{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-025302","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2026-08-03T11:02:13+00:00","discovered_at":"2026-08-03T11:05:00.299865+00:00","generated_at":"2026-08-03T11:05:21.935883+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Genprex collaborates with Roche Diagnostics to validate TROP2/PTEN biomarkers for NSCLC","bullets":["Collaboration with Roche Diagnostics to validate TROP2 and PTEN biomarkers for patient selection in NSCLC clinical trials.","Roche's AI-driven companion diagnostic received FDA Breakthrough Device Designation; Genprex will use same TROP2 antibody.","Validation studies expected to complete by end of 2026, with subsequent integration into NSCLC clinical program.","Preclinical data: high TROP2 H-scores and low PTEN H-scores predicted response; clinical data correlated with longer PFS.","Goal to shorten patient identification and recruitment for NSCLC trials, enabling more personalized treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-025302","json":"https://secwatch.observer/filing/0001437749-26-025302.json","markdown":"https://secwatch.observer/filing/0001437749-26-025302.md","text":"https://secwatch.observer/filing/0001437749-26-025302.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926025302/0001437749-26-025302-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926025302/gnpx20260802_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T11:05:21.935883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}